INNOGEN's core products officially enter commercial sales in Macau
INNOGEN-B (02591.HK) announced that the first prescription for its core product, Isupegaglutide α, used for the treatment of type 2 diabetes, has been issued at the Huabao Medical Center in Macau, marking the official entry of the core product into the commercialization phase in Macau
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments